Content about Ofatumumab

April 21, 2014

GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.

September 8, 2010

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

June 30, 2010

British drug maker GlaxoSmithKline has inked a co-development and commercialization agreement with Genmab, the drug...

February 18, 2010

The Food and Drug Administration has approved a drug made by Roche subsidiary Genentech and...

© 2014 Drug Store News. All Rights Reserved.